EP Patent

EP0574174A2 — Angiotensin II antagonists

Assigned to Eli Lilly and Co · Expires 1993-12-15 · 32y expired

What this patent protects

This invention provides pharmaceutical heterocyclic derivatives of the formula in which R₃ are specified nitrogen-containing fused rings. They antagonize angiotensin II receptors in mammals.

USPTO Abstract

This invention provides pharmaceutical heterocyclic derivatives of the formula in which R₃ are specified nitrogen-containing fused rings. They antagonize angiotensin II receptors in mammals.

Drugs covered by this patent

Patent Metadata

Patent number
EP0574174A2
Jurisdiction
EP
Classification
—
Expires
1993-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.